A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

Ajuts: This study was sponsored by Pfizer Inc. This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients w...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Wainberg, Zev A, Alsina, Maria, Soares, Heloisa P, Braña, Irene, Britten, Carolyn D, Del Conte, Gianluca, Ezeh, Patrick, Houk, Brett, Kern, Kenneth A, Leong, Stephen, Pathan, Nuzhat, Pierce, Kristen J, Siu, Lillian L, Vermette, Jennifer, Tabernero, Josep, Universitat Autònoma de Barcelona
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!